A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled,
multicenter study to evaluate the efficacy, safety, and tolerability of single doses of
STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.